返回 
加入收藏
基于化疗相关问题建立药学监护路径
x
请在关注微信后，向客服人员索取文件
| 篇名： | 基于化疗相关问题建立药学监护路径 |
| TITLE： | Establishment of pharmaceutical care pathway based on the problems related to chemotherapy |
| 摘要： | 目的 设计化疗相关问题药学监护路径并评估其是否有助于发现并干预化疗患者的药物相关问题（DRPs）。方法通过药学监护实践经验建立并实施化疗相关问题药学监护路径表与流程图。将该药学监护路径实施前后入住我院接受化疗的患者分为对照组（实施前，60例）与观察组（实施后，64例），提取对照组患者相关病历用以评估DRPs，对观察组患者进行化疗相关问题药学监护并提取DRPs。比较两组患者的基本情况、化疗情况、DRPs类别与干预情况、化疗所致不良反应、DRPs的欧洲医药保健网（PCNE）分类、DRPs发生时间、DRPs涉及的药物类别。结果两组患者的基本情况、化疗方案与化疗药物类别比较，差异均无统计学意义（P＞0.05）。对照组与观察组分别有46、37例患者发生DRPs。两组DRPs均主要发生在化疗期间，且主要为化疗前期。利用化疗相关问题药学监护路径，DRPs的识别率从对照组的52.17%显著提高至观察组的91.89%（P＜0.05），干预率从对照组的32.61%显著提高至观察组的72.97%（P＜0.05），不良反应发生率从对照组的28.33%显著降低至观察组的12.50%（P＜0.05）。对照组DRPs的主要问题类型为治疗有效性，主要涉及药物为辅助抗肿瘤药，主要发生原因为超适应证给予辅助抗肿瘤药；观察组DRPs的主要问题类型为治疗有效性和治疗安全性，主要涉及药物为止吐药，主要发生原因为预防化疗所致恶心呕吐用药不足。结论化疗相关问题药学监护路径的实施有助于临床药师更好地识别与干预化疗患者的DRPs，减少化疗所致不良反应的发生。 |
| ABSTRACT： | OBJECTIVE To design pharmaceutical care pathway for the problems related to chemotherapy， and to evaluate whether it contributes to the detection and intervention of drug-related problems （DRPs） in chemotherapy patients. METHODS The pharmaceutical care pathway table and flow charts were constructed and implemented by pharmaceutical care practice experience. The patients who were admitted to our hospital for chemotherapy before and after the implementation of the pharmaceutical care pathway were divided into control group （before the implementation，60 cases） and observation group （after the implementation，64 cases）， respectively； the relevant medical records of patients in the control group were extracted to evaluate DRPs， and pharmaceutical care of chemotherapy-related problems was performed for patients in observation group to extract DRPs. The basic condition， chemotherapy condition， DRPs classification and intervention status， adverse reactions induced by chemotherapy， PCNE classification of DRPs， occurrence time of DRPs， and drug classes related to DRPs were compared between 2 groups. RESULTS There was no statistical significance in the basic situation， chemotherapy regimen and chemotherapy drug category between the two groups （P＞0.05）. DRPs occurred in 46 and 37 patients in control group and observation group， respectively. In both groups， DRPs mainly occurred during chemotherapy， and mainly in the early stage of chemotherapy. Using the new pathway， the detection of DRPs significantly increased from 52.17% in the control group to 91.89% in the observation group （P＜0.05）. The successful intervention rate of DRPs was significantly increased from 32.61% in the control group to 72.97% in the observation group （P＜ 0.05）. The incidence of adverse drug reactions significantly decreased from 28.33% in the control group to 12.50% in the observation group（P＜0.05）. The main problem type of DRPs in the control group was treatment effectiveness， which mainly involved adjuvant antitumor drugs， mainly due to the use of adjuvant anti-tumor drugs for off-label prescribing； that of the observation group was treatment effectiveness and treatment safety， which mainly involved vomiting drugs， mainly due to insufficient medication to prevent nausea and vomiting caused by chemotherapy. CONCLUSIONS The implementation of the pathway helps clinical pharmacists to detect and intervene in DRPs among chemotherapy patients， and reduces the occurrence of chemotherapy-induced adverse reactions. |
| 期刊： | 2024年第35卷第03期 |
| 作者： | 陈雅；杨婷蓉；赵华；王莹 |
| AUTHORS： | CHEN Ya，YANG Tingrong，ZHAO Hua，WANG Ying |
| 关键字： | 药学监护路径；临床药师；药学监护；化疗相关问题 |
| KEYWORDS： | pharmaceutical care pathway； clinical phar- |
| 阅读数： | 60 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
